Candel Therapeutics Inc. (CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, is expected to share updates on its clinical programs - CAN-2409 and CAN-3110 - this year.
CAN-2409 is an off-the-shelf adenovirus product candidate, which is administered in conjunction with the prodrug valacyclovir, that has generated promising clinical activity across a range of solid tumor indications. It is being explored in the indications of prostate cancer, non-small cell lung cancer and pancreatic cancer.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.